{"entity":{"id":"nct06317311","kind":"trial","name":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer","aka":[],"tldr":"A phase 2 trial of Dostarlimab and Carboplatin in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.","summary":"A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer is a phase 2 interventional study registered as NCT06317311 by GlaxoSmithKline, with 41 participants enrolled, started 2024-05-07 and due to reach its primary completion in 2026-07-15. Interventions recorded: Dostarlimab, Carboplatin and Paclitaxel.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06317311","url":"https://clinicaltrials.gov/study/NCT06317311"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["dostarlimab","carboplatin"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06317311","phase":"2","setting":"A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Japanese Patients With Primary Advanced or Recurrent Endometrial Cancer (RUBY-J)","sponsor":"GlaxoSmithKline","enrolled":41,"outcomes":[]},"route":"/trials/nct06317311/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"dostarlimab","kind":"drug","name":"Dostarlimab","route":"/drugs/dostarlimab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}